Technoderma Medicines, Inc.is a clinical stage biopharmaceutical company.

The company's current core research and development programs include innovative drugs for the treatment of androgenic alopecia, eczema/atopic dermatitis, psoriasis and lupus. TDM-105795, the world's leading small-molecule drug candidate for the treatment of androgenic alopecia, has now completed 2a clinical trials. TDM-180935, a novel JAK1/TYK2 inhibitor for eczema/atopic dermatitis, has also completed a Phase 1 clinical trial in December 2023 with favorable safety results, and Phase 2 a POC clinical trials are underway in the United States.